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Phase-I trials traditionally involve dose-escalation to determine the maximal tolerated dose (MTD). With conventional chemotherapy,
efficacy is generally deemed to be dose-dependent, but the same may not be applicable to molecularly targeted agents (MTAs). We
analysed consecutive patients included in Phase-I trials at the Royal Marsden Hospital from 5 January 2005 to 6 June 2006. We
considered only trials of monotherapy MTAs in which the MTD was defined. Three patient cohorts (A, B, and C) were identified
according to the dose received as a percentage of the final trial MTD (0–33%, 34–65%, 466%). Potential efficacy was assessed using
the non-progression rate (NPR), that is, complete/partial response or stable disease for at least 3 months by RECIST. A total of 135
patients having progressive disease before enrolment were analysed from 15 eligible trials. Median age was 57 years (20–86);
male:female ratio was 1.8:1. Cohort A, B, and C included 28 (21%), 22 (16%), and 85 (63%) patients; NPR at 3 and 6 months was
21% and 11% (A), 50% and 27% (B), 31% and 14% (C), respectively, P¼0.9. Median duration of non-progression (17 weeks; 95%
CI¼13–22) was not correlated with the MTD level, P¼0.9. Our analysis suggests that the potential for clinical benefit is not
confined to patients treated at doses close to the MTD in Phase-I trials of MTAs.
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The aim of Phase-I trials is to determine the optimal recommended
Phase-II dose (RP2D) of a new compound for further clinical
investigation. For cytotoxic drugs, this dose traditionally corres-
ponds to the highest dose associated with an acceptable level
of toxicity and is derived from clinical data and preclinical
dose-toxicity and dose-activity studies (Korn et al, 2001). For
conventional cytotoxic agents, in vitro data and preclinical models
using cell lines showed that higher exposure to a drug generally
increases tumour cell kill; this dose–response relationship was
extrapolated to humans and oncologists have widely adhered to
the principle that ‘more is better’. Indeed, recent observations
showed that the majority of responses occurred at 75–125% of the
RP2D, and that the RP2D was usually the maximal tolerated dose
(MTD) (Von Hoff and Turner, 1991; Itoh et al, 1994; Parulekar
and Eisenhauer, 2004).
Unlike classical chemotherapy agents, new molecularly targeted
agents (MTA) are based on different mechanisms and are often
considered to be cytostatic rather than cytotoxic. Clinically, this
implies that the radiological evaluation of their efficacy by RECIST
criteria should include not only a reduction in tumour size, but
also non-progression (NP) or disease stabilisation. Therefore, the
NP rate (NPR), defined as tumour response plus stable disease
(SD), could be a relevant measure of response as well as a potential
indicator for clinical benefit.
These novel MTA are often characterised by clinically
relevant organ toxicities, which differ from the antiproliferative
toxicities seen with cytotoxic chemotherapy, and MTD is not
always reached (Booth et al, 2008). Thus, the determination of
the RP2D based only on toxicity as surrogate marker for activity
in the conventional Phase-I setting may be inappropriate for
these agents. Moreover, it is unclear whether the RP2D based on
toxicity is close to the optimal active dose, as this is derived from a
linear dose–efficacy relationship assumption, which may not be
relevant for these novel compounds (Parulekar and Eisenhauer,
2004; Cannistra, 2008). Therefore, some authors have advocated
establishing a dose range, combining toxicity data – defining the
upper limit – and pharmacodynamic and pharmacokinetic data
– defining lower dose levels, which could be tested in a randomised
Phase-II trial (Booth et al, 2008).
Although it is widely agreed that demonstration of anti-tumor
activity is not the primary endpoint of Phase-I trials, both patients
and physicians hope for benefits from treatment : a discussion
about the chances of benefit – that is, tumour response or disease
control – is always included in the conversation with Phase-I
candidates (Agrawal and Emanuel, 2003). The ethics and
individual merits of Phase-I trials have been extensively debated
during the ‘era’ of cytotoxic drugs development, and it has been
reported that up to 60% of the patients could be treated at sub-
therapeutic dose levels (Agrawal and Emanuel, 2003; Koyfman
et al, 2007). Efforts to minimise the number of patients treated at
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ssub-therapeutic doses and required to reach the MTD have lead to
the development of different trial designs such as the continuous
reassessment method (Potter, 2002).
The purpose of this study was to investigate whether, in the era
of MTA, the chance of benefit in Phase-I trials depended on the
dose received, that is, was there any detriment for patients enroled
at early dose levels.
PATIENTS AND METHODS
Study design, patients, and trials eligibility criteria
This retrospective study considered all consecutive patients
evaluable for response and treated in at least one Phase-I trial in
the Drug Development Unit at The Royal Marsden Hospital
(RMH), United Kingdom, from 5 January 2005 to 6 June 2006.
From our database, we selected only patients who were included in
trials meeting the following criteria: (1) Trials studying an MTA –
an MTA being defined as any agent with any extra- or intracellular
target different from those associated with conventional chemo-
therapy (DNA, tubulin, or cell division machinery); actual tumour
shrinkage as opposed to stasis in an experimental model was not
a pre-requisite; (2) Trials in which the MTD was described; (3)
Trials evaluating an MTA in monotherapy (combinations with
conventional chemotherapy or radiotherapy were excluded); and
(4) Trials in which the dose escalation method allowed an easy
comparison in terms of MTD percentage. All MTD levels were
defined individually for each trial on the basis of the protocol MTD
definition. All the patients in our analysis had evidence of disease
progression before trial entry. Several clinical parameters were
collected at study entry, including tumour type, age, sex, ECOG
performance status, full blood count, biochemistry (lactate
dehydrogenase, and albumin), number and sites of metastasis,
and number of earlier systemic cancer treatments. Using these
data, we were able to apply our recently validated RMH prognostic
score (Arkenau et al, 2009).
We analysed the NPR, a combination of complete response,
partial response (PR), and SD, at the first assessment after trial
entry, and at 3 and 6 months. We considered the NPR at 43
months as a potential indicator for clinical benefit.
All Phase-I trials included in this analysis were approved by the
Research and Development Committee and Ethics Committee of
the RMH. This analysis received approval of the RMH audit
committee.
Patients’ evaluation and follow-up
All patients underwent regular follow-up and assessment of the
disease was carried out by CT (RECIST criteria (Therasse et al,
2000) before trial entry, and every 6 to 8 weeks depending on
protocol requirements. For prostate cancer patients, PSAWG
criteria (Bubley et al, 1999) were allowed for the definition of
progressive disease, but not for disease response.
Statistical analysis
Three cohorts (A: 0–33%, B: 34–66%, and C: 467% of the MTD)
were defined according to the percentage of the final MTD received
by each patient. The percentage of MTD was not considered as a
continuous variable, as the distribution of the different dose levels
did not follow a regular pattern between 0 and 100% of the MTD.
The Kaplan–Meier method and log-rank trend tests were used to
compare the NPR, progression-free survival (PFS), and overall
survival (OS) for all the patients between the three cohorts with a
threshold for significance of P¼0.05. PFS and OS for all patients
were measured from trial entry until documented progression (by
RECIST or PSAWG criteria) and death, respectively. For relevant
patients, the duration of NP and survival were measured from the
first administration of the study drug. The Kendall-t correlation
test was used to compare the distribution of the RMH Prognostic
Score between the three cohorts. Statistics were carried out using
the SPSS-Program (version 15.0, Chicago, IL, USA). The cut-off
date for the present analysis was 7 July 2007.
RESULTS
Trials Characteristics
Between 5 January 2005 and 6 June 2006, 29 Phase-I trials (252
patients) were open for recruitment in our unit. We excluded 14
trials (117 patients) based on the earlier defined trial eligibility
criteria (Figure 1): 10 trials involved conventional chemotherapy
or radiotherapy in combination with an MTA; two trials
investigating a virus used a logarithmic dose-escalation scales;
two trials involving MTA did not reach the MTD.
The evaluable 15 trials (135 patients) investigated a variety of
MTAs including epithelial growth factor receptor inhibitors, anti-
angiogenic agents, heat shock protein (HSP90) inhibitors, insulin-
like growth factor receptor inhibitors, poly(ADP-ribose) polymer-
ase inhibitors, or epigenetic modulators (Table 1). In total, 12 trials
investigated small molecule tyrosine kinase inhibitors. For 12 trials
(113 patients), the MTD was defined as ‘the highest dose level
below that at which fewer than 2 or more patients experience a
DLT’ and for three trials (22 patients), the MTD was defined as ‘the
dose at which at least 2 out of 6 patients experience a DLT’.
Overall, the median number of dose levels was 5 (range: 4–9).
Patients’ characteristics
The characteristics of the 135 eligible patients were as follows: the
median age was 57 years (range: 20–86) with a male:female ratio
29 Phase I Trials
open for recruitment
252 patients recruited
from jan 2005 to jun 2006
10 trials excluded
involving new chemotherapy-like
 drugs or combinations with
chemo- or  radiotherapy
69 patients excluded
2 trials excluded
involving viral therapy
 with logarithmic dose-escalation
23 patients excluded
2 trials excluded
involving biological agents
for which a MTD was not defined
25 patients excluded
15 eligible phase I trials
135 eligible patients 
Figure 1 Overview of trial/patient database.
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sof 1.8:1. The majority of patients had an ECOG PS of 1 (63%) and
only 10% of patients had a PS of 2. The median number of earlier
therapies was 2 (range: 0–8) and patients presented with a broad
spectrum of tumour types (Table 2).
Cohorts
Cohorts A, B, and C included 28 (21%), 22 (16%), and 85 (63%)
patients, respectively. The larger number of patients included in
cohort C is related to the fact that most trials dose expanded at the
MTD level. The patients’ characteristics and the RMH prognostic
score were not significantly different in the three cohorts reflected
by a Kendall-t coefficient of  0.032 (P¼NS) (Table 3).
Responses, non-progression rate, and survival
Non-progression rate The median follow-up time of this analysis
was 69 weeks. A total of 23 patients (17%) were not evaluable for
disease response because of early clinical progression (13 patients),
toxicity (five patients including three DLTs), or death (five
patients). Nine patients with prostate cancer progressed on PSA
measurement according to PSAWG criteria, without radiological
progression.
The NPR for the entire population, at 3 months and 6 months
was 32% (43 patients) and 16% (21 patients), respectively. The
NPR for the three cohorts at 3 and 6 months was not significantly
different, P¼0.9 (Cohort A: 21% (6 patients) and 11% (3 patients);
Cohort B: 50% (11 patients) and 27% (6 patients); Cohort C: 31%
(26 patients) and 14% (12 patients), respectively (Table 3). The
results of patients with no progression at 3 months are shown as a
waterfall plot, in Figure 2. The median duration of NP for all
patients was 17 weeks (95% CI: 13–22) (Cohort A: 23 weeks (95%
Table 1 Trials’ characteristics
Number of trials N¼15
Trials’ characteristics N
Drug target
EGFR 2
VEGFR2 2
VEGF 1
HSP90 1
IGF-1R 1
HDAC 1
DNA methytransferase 1
PARP 1
TRAIL-R2 1
5a-hydroxylase/C17,20lyase 1
Rho-GTP dependant factor 1
Farnesyl transferase 1
Aminopeptidase 1
Class of agent
Small molecule TKIs 12
Monoclonal antibodies 2
ASO 1
Number of dose levels
4 dose levels 3
5 dose levels 6
6 dose levels 2
8 dose levels or more 4
Dose escalation method
Modified fibonacci 1
Accelerated titration 9
Pre-established dose levels increments 5
ASO¼antisense oligodeoxynucleotide; EGFR¼epithelial growth factor receptor;
HDAC¼histone deacetylase; HSP90¼heat shock protein inhibitor; IGF-IR¼insulin-
like growth factor receptor inhibitor; PARP¼poly(ADP-ribose) polymerase inhibitor;
TKIs¼tyrosine kinase inhibitors; TRAIL-R2¼TNF-related apoptosis inducing ligand-
receptor 2; VEGF¼vascular endothelial growth factor; VEGFR2¼vascular endothe-
lial growth factor receptor 2.
Table 2 Patients’ characteristics
Number of patients N¼135
Patients’ characteristics Total (%)
Age
Median (range) 57 (20–86)
Sex
Male 87 (64%)
Female 48 (36%)
Performance status (ECOG)
0 37 (27%)
1 85 (63%)
2 13 (10%)
Earlier therapy
Median (range) 2 (0–8)
Tumour type
Breast and gynaecological 24 (18%)
Prostate 21 (16%)
Sarcoma 21 (16%)
Thoracic 20 (15%)
Gastro-intestinal 15 (11%)
Renal 12 (8%)
Melanoma 5 (4%)
Others 17 (13%)
RMH Prognostic score
0 16 (12%)
1 38 (28%)
2 51 (38%)
3 30 (22%)
ECOG¼Eastern cooperative oncology group; RMH¼Royal Marsden Hospital
prognostic score.
Table 3 Patients’ distribution and MTD cohorts
Cohort A Cohort B Cohort C Total
Number of patients (%)
28 (21%) 22 (16%) 85 (63%) 135
Gender (male/female)
15/13* 13/9* 59/26* 87/48
Age (median (range))
60 (20–83) 56 (27–77) 57 (25–86) 57 (20–86)
Performance status
ECOG 0 6* 6* 22* 34
ECOG 1 17* 12* 51* 80
ECOG 2 5* 2* 3* 10
RMH Prognostic score
0–1 10 (36%)
w 9 (41%)
w 35 (40%)
w 54 (40%)
2–3 18 (64%)
w 13 (59%)
w 51 (60%)
w 81 (60%)
Non-progression rate
3-month NPR 6 (21%)
z 11 (50%)
z 26 (31%)
z 43/135 (32%)
6-month NPR 3 (11%)
z 6 (27%)
z 12 (14%)
z 21/135 (16%)
Objective responses
131 5
ECOG¼Eastern cooperative oncology group; MTD¼maximal tolerated dose;
RMH¼Royal Marsden Hospital, NPR¼non-progression rate. *P¼0.1.
wP¼0.7.
zP¼0.9.
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weeks (95% CI: 12–18)), P¼0.9. Prolonged NP (46 months) were
seen in patients included in nine different trials, each of them
comprising between 4 and 9 dose levels.
Responses Overall, five patients experienced PR (one in cohort A,
three in cohort B, and one in cohort C). They were included in
three different trials, comprising of 5, 4, and 8 dose levels.
Progression-free survival The median PFS was 10 weeks (95% CI:
8–12) for the entire population (Cohort A: 6 weeks (95% CI: 5–7);
Cohort B: 13 weeks (95% CI: 8–17); Cohort C: 10 weeks (95% CI:
8–12)), P¼0.09, Figure 3A.
Overall survival Overall survival was 38 weeks (95% CI: 27–49)
for the entire population and was not different between the three
cohorts (Cohort A: 30 weeks (CI 95% 18–43); Cohort B: 48 weeks
(CI 95%, 28–68); Cohort C: 41 weeks (CI 95% 28–54)), P¼0.7,
Figure 3B.
DISCUSSION
Phase-I trials have been developed and designed in the era of
conventional cytotoxic drug development (Eisenhauer et al, 2000).
Increasingly, they now include novel MTAs and several challenging
questions need to be addressed in this context. Our retrospective
analysis investigated whether there was any correlation between
the potential for clinical benefit derived from Phase-I treatment
and the actual dose that patients received. Patients were divided in
three cohorts depending on the percentage of the final MTD of the
drug received and we studied the NPR, duration of NP, and
response. In summary, we did not observe any statistical
differences in the NPR at 3 or 6 months and in the time of NP
for the three cohorts. These results support the hypothesis that in
the era of Phase-I trials studying MTAs, patients could derive
prolonged disease stabilisation, and thus potential for clinical
benefit even on lower dose levels; this in turn may influence the
way current Phase-I cancer trials are planned, implemented, and
analysed.
Our data could also have implications in the way Phase-I trials
are discussed with patients before trial entry. Many patients would,
if given the choice, prefer being enroled at higher dose levels rather
than at lower levels, in which the dose administered is thought to
be insufficient. The fact that we could not show any detriment for
patients enroled at lower dose levels may result in an enhanced
acceptability of entry at initial stages.
In addition, our data emphasise the importance of identifying
a biologically active dose in Phase-I trials of MTA (Ratain and
Glassman, 2007; Banerji et al, 2008; Cannistra, 2008), as this
may be significantly different from the MTD (Slaton et al, 1999).
Clinically, the most effective dose will vary across this range
according to the type of agent. Generally, novel MTAs may have a
broader therapeutic range compared with conventional cytotoxic
agents, and clearly the use of a lower dose could limit the risk of
both late and cumulative toxicities using MTAs either as single
agents or in combination with conventional chemotherapy or
radiotherapy (Cannistra, 2008). At this stage, however, Phase-I
trials of MTAs, as well as involving detailed pharmacodynamic and
pharmacokinetic analysis, should continue to have the determina-
tion of MTD as a primary aim. Subsequent decisions regarding
RP2D will vary according to the agent, and randomised
Phase-II trials may well be appropriate (Haines, 2008; Sleijfer
and Wiemer, 2008).
An alternative conclusion from our study is that the clinical
outcome in our patients was not influenced by the Phase-I trial
treatment at all. Indeed, this could explain the absence of
significant difference in the NPR between the three cohorts, but
would not explain the fact that radiological measurable response
was seen in some patients, and not exclusively at the MTD level.
Nowadays, randomised Phase-II trials evaluating MTAs use, as
primary objective, the PFS – or Time To Progression – to
determine if the drug deserves further evaluation in a randomised
Phase III setting (Korn et al, 2001; Ratain and Glassman, 2007).
However, we acknowledge that the NPR at 3 and 6 months is a
difficult and insufficiently validated measure of clinical benefit and
that it would be strengthened by larger numbers, as well as data on
symptomatic and/or performance status improvement. A poten-
tially helpful tool to evaluate clinical benefit using PFS was
proposed several years
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Figure 2 Best response at 3 months (Cohort A, B, and C). This waterfall plot represents the patients remaining progression free during the first
3 months on treatment; the column’s colour corresponds to the dose-level cohort.
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sago and entitled the Growth Modulation Index (GMI) (Von Hoff,
1998; Mick et al, 2000). The GMI – defined by the ratio
TTP(1):TTP(2), in which TTP(1) and TTP(2) are, respectively,
the TTP before and after starting a treatment – compares the rate
of change of a tumour lesion before and after Phase-I treatment. It
is suggested that a GMI 41.3 reflects treatment effect. Although
not yet validated, we applied this methodology to a subgroup of
our patients in whom radiological imaging was completely
available. In our series, the GMI for patients who experienced
disease control for 46 months was 3.1 (range 1.0–9.4), suggesting
that these patients had a ‘real’ drug benefit, whereas patients
who progressed between 3 and 6 months had a GMI of 1.1 (range
0.3–3.0; 15 patients evaluable). Despite the small patient numbers
and the lack of conformity of measurements of tumour progres-
sion before Phase-I trial entry, we believe that this methodology
deserves further careful evaluation.
A last point to address is the fact that this data set is small and it
is possible that the number of patients included in this analysis did
not allow us to observe significant differences in dose response. To
explore this further, we repeated this analysis by dividing the
patients in two groups (4 or p50% of the MTD), which allowed
us to increase the number of patients per group. Here again, we
could not see any statistically significant difference between the
two groups with regards to the 3 and 6 months NPR (data not
shown). We acknowledge, however, that these data, as they derive
from a retrospective single-centre analysis, have to be interpreted
cautiously and that our study can only allow the generation of
hypotheses. Therefore, we would strongly encourage further
validation in larger cohorts.
In summary, our results raise the possibility that the potential for
clinical benefit, as measured by NPR and radiological responses, is
not confined to patients treated at doses close to the MTD in Phase-I
trials of novel MTAs. Whether a prolonged NP leads to a true clinical
benefit for the patient is still unclear and deserves further careful
evaluation. If validated, this could potentially impact on the
discussion between clinicians and patients who are candidates for
Phase-I trials. It also reinforces the need to study the biologically
effective doses in addition to MTD. Further validation, in larger
cohorts and revisiting Phase-I data of MTAs, which have already
shown efficacy in Phase-II/III trials, is warranted.
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